Effective at the market close on Wednesday, April 1, 2020, RARX will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On October 10, 2019, RA Pharmaceuticals agreed to be acquired by UCB for $48 per share in cash.
